Discovery and development of cancer therapeutics for next program
Active Awarded Last action
- Contract number
- 75N91022F00019
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $22,364,766
Award facts
- Contract value 100% obligated
- $22,364,766.00 Current and potential, with all options
- Completion date 82% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21703, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Original award | $22,364,766 |
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 9, 2022, with a ceiling value of $22.4 million for discovery and development of cancer therapeutics under a Cost Plus Fixed Fee pricing structure. The order's ultimate completion date is September 8, 2027.
Place of performance is Frederick, Maryland. Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center (FFRDC) contractor for NCI and provides biomedical research and facilities support, with particular expertise in cancer research, gene therapy development, clinical trials, and specialized laboratory testing.
Service Contract Inventory reporting shows actual government-invoiced labor of $5 thousand in FY2023 (0.0 FTEs, 52 contractor hours) and $1.3 million in FY2024 (2.2 FTEs, 4,529 contractor hours). The derived government-paid hourly rate rose from $103.29 per hour in FY2023 to $285.84 per hour in FY2024, reflecting an upward trend. In FY2024, the order engaged 2 subcontractors, with 94 percent of contractor hours subcontracted out.
Quick answers
Who was awarded contract 75N91022F00019?
75N91022F00019 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 9, 2022.
How much is contract 75N91022F00019 worth?
The government has obligated $22,364,766 on 75N91022F00019.
Is contract 75N91022F00019 an order under another contract?
Yes. 75N91022F00019 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00019 competed?
The extent of competition for 75N91022F00019 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award